That in itself is a very important factor in the entire discussion
Because the known RP genetic heterogeneity makes developing RP therapeutics rather challenging, gene-independent approaches (e.g., neuroprotective agents, retinal implants, gene therapy, dietary supplements, low-vision aids, and rehabilitation) aiming to treat a wider patient population have become more appealing 2,4,5,6,7,8
Europe Perspectives du March : L'impulsion rglementaire sur les antioxydants valids cliniquement soutient une adoption constante
Acknowledgements The authors would like to thank Dr
For almost a century, not one harmful case of overdose has been recorded in medical literature